Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25114201 | 0.86 | KDM4E (0.50) | ATMPSMD14KDM4EALDH1A1CCR1 | |
| SCHEMBL18458802 | 0.85 | PSMD14 (0.44) | ATMPSMD14KDM4EALDH1A1TDP1 | |
| SCHEMBL17442622 | 0.85 | ATM (0.51) | ATMPSMD14KDM4EALDH1A1CCR1 | |
| SCHEMBL23196190 | 0.85 | PSMD14 (0.44) | ATMPSMD14KDM4EALDH1A1TDP1 | |
| SCHEMBL23905404 | 0.85 | ATM (0.47) | ATMPSMD14KDM4EALDH1A1CCR1 | |
| SCHEMBL23195624 | 0.82 | HCAR2 (0.46) | PSMD14KDM4EALDH1A1CCR1CCR5 | |
| SCHEMBL18371184 | 0.81 | MAPT (0.47) | ATMPSMD14KDM4EL3MBTL1MAPK1 | |
| SCHEMBL23196217 | 0.81 | ATM (0.44) | ATMPSMD14KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL23905543 | 0.79 | ATM (0.42) | ATMPSMD14KDM4EALDH1A1CCR1 | |
| SCHEMBL25687961 | 0.78 | ATM (0.41) | ATMPSMD14KDM4EALDH1A1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3169325-B1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-10308637-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-06-04 | — | — | US | disclosed |
| US-10266515-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-04-23 | — | — | US | disclosed |
| US-10259803-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-04-16 | — | — | US | disclosed |
| US-20190002437-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| US-10023557-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-07-17 | — | — | US | disclosed |
| US-20180170906-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20170260163-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9611252-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-04-04 | — | — | US | disclosed |
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308637-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | ATM 1219/4885PSMD14 1813/4885KDM4E 798/4885 |
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | ATM 1219/4885PSMD14 1813/4885KDM4E 798/4885 |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | ATM 1219/4885PSMD14 1813/4885KDM4E 798/4885 |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | ATM 1219/4885PSMD14 1813/4885KDM4E 798/4885 |
| US-20180170906-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | ATM 1219/4885PSMD14 1813/4885KDM4E 798/4885 |
| US-10023557-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | ATM 1219/4885PSMD14 1813/4885KDM4E 798/4885 |
| US-20170260163-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | ATM 1219/4885PSMD14 1813/4885KDM4E 798/4885 |
| US-10266515-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | ATM 1219/4885PSMD14 1813/4885KDM4E 798/4885 |
| US-10259803-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | ATM 1219/4885PSMD14 1813/4885KDM4E 798/4885 |
| US-20190002437-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | ATM 1219/4885PSMD14 1813/4885KDM4E 798/4885 |
| US-11021463-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | ATM 1219/4885PSMD14 1813/4885KDM4E 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.